换一批
换一批Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
作者：
主题词
动物(Animals);抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);曲线下面积(Area Under Curve);印迹法, 蛋白质(Blotting, Western);喜树碱(Camptothecin);细胞系, 肿瘤(Cell Line, Tumor);细胞增殖(Cell Proliferation);结直肠肿瘤(Colorectal Neoplasms);脱氧胞苷(Deoxycytidine);剂量效应关系, 药物(Dose-Response Relationship, Drug);抗药性, 肿瘤(Drug Resistance, Neoplasm);氟尿嘧啶(Fluorouracil);HCT116细胞(HCT116 Cells);HT29细胞(HT29 Cells);人类(Humans);吲哚类(Indoles);Kaplan-Meiers评估(Kaplan-Meier Estimate);小鼠(Mice);小鼠, 裸(Mice, Nude);丝裂原激活蛋白激酶类(Mitogen-Activated Protein Kinases);突变(Mutation);磷酰化(Phosphorylation);原癌基因蛋白质B-raf(Proto-Oncogene Proteins B-raf);喹唑啉类(Quinazolines);磺胺类(Sulfonamides);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays)
DOI
10.1158/0008-5472.CAN-11-2941
PMID
22180495
发布时间
2018-12-01
- 浏览51
Cancer research
779-89页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
